Dr. Amado Katigbak Jr., MD

Dr. Katigbak practices at Silverdale Medical Center in Silverdale, Washington.

Dr. Katigbak's NPI, 1538227939, was assigned on December 5, 2006. Dr. Katigbak holds Washington license MD00040185.

Dr. Katigbak's primary practice is Silverdale Medical Center, at 10452 Silverdale NW Way, Silverdale, WA 98383 in Kitsap County. The practice phone is (360) 307-7300.

Dr. Katigbak's primary practice is Silverdale Medical Center in Silverdale, Washington. The medical group on file is Washington Permanente Medical Group, P.C. Dmand AI also links Dr. Katigbak to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Katigbak practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Katigbak's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Katigbak is licensed in Washington.

CMS data shows 14 Medicare services from Dr. Katigbak across 1 procedure code in 2024, all of them office visits, for 32 Medicare patients. Medicare paid $707 for them. Every service was in an office.

CMS counts 32 Medicare patients who saw Dr. Katigbak in 2024. The largest group is 65 to 74, with 14 patients. 59% of them have high blood pressure, and 47% have arthritis. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Katigbak's median patient age at 77, with 57% women.

In 2024, Dr. Katigbak wrote 2,220 Medicare Part D claims for 213 patients. 89% of them were for generic drugs. CMS names the drug for 1,749 of them, across 49 drugs with 11 or more claims each, at $64,122 in total drug cost. In 2023, CMS named 2,292 claims across 68 drugs.

Dr. Katigbak accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Katigbak as offering telehealth.

CMS Open Payments shows 1 general payment to Dr. Katigbak from 1 drug or device company in 2023. Food and beverage make up the largest share, 100% of the total. Aurinia Pharma U.S., Inc. paid the most, $86.